CA2886442A1 - Generation de nouvelles cellules beta du pancreas - Google Patents

Generation de nouvelles cellules beta du pancreas Download PDF

Info

Publication number
CA2886442A1
CA2886442A1 CA 2886442 CA2886442A CA2886442A1 CA 2886442 A1 CA2886442 A1 CA 2886442A1 CA 2886442 CA2886442 CA 2886442 CA 2886442 A CA2886442 A CA 2886442A CA 2886442 A1 CA2886442 A1 CA 2886442A1
Authority
CA
Canada
Prior art keywords
seq
peptide
amino acid
antibody
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2886442
Other languages
English (en)
Inventor
Claresa LEVETAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/662,253 external-priority patent/US9133440B2/en
Priority claimed from US13/662,232 external-priority patent/US20140120560A1/en
Priority claimed from US13/662,245 external-priority patent/US9511110B2/en
Priority claimed from US13/662,209 external-priority patent/US8911776B2/en
Application filed by Individual filed Critical Individual
Publication of CA2886442A1 publication Critical patent/CA2886442A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/474Pancreatic thread protein; Reg protein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA 2886442 2012-09-27 2013-09-26 Generation de nouvelles cellules beta du pancreas Abandoned CA2886442A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261706225P 2012-09-27 2012-09-27
US61/706,225 2012-09-27
US13/662,253 US9133440B2 (en) 2012-09-27 2012-10-26 Generation of new pancreatic beta cells
US13/662,232 US20140120560A1 (en) 2012-10-26 2012-10-26 Generation of new pancreatic beta cells
US13/662,245 2012-10-26
US13/662,232 2012-10-26
US13/662,245 US9511110B2 (en) 2012-09-27 2012-10-26 Generation of new pancreatic beta cells
US13/662,209 US8911776B2 (en) 2012-09-27 2012-10-26 Generation of new pancreatic beta cells
US13/662,209 2012-10-26
US13/662,253 2012-10-26
PCT/US2013/061947 WO2014052611A1 (fr) 2012-09-27 2013-09-26 Génération de nouvelles cellules bêta du pancréas

Publications (1)

Publication Number Publication Date
CA2886442A1 true CA2886442A1 (fr) 2014-04-03

Family

ID=50388965

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2886442 Abandoned CA2886442A1 (fr) 2012-09-27 2013-09-26 Generation de nouvelles cellules beta du pancreas

Country Status (5)

Country Link
EP (1) EP2900691A4 (fr)
JP (1) JP2015533821A (fr)
AU (1) AU2013323462A1 (fr)
CA (1) CA2886442A1 (fr)
WO (1) WO2014052611A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104614523B (zh) * 2014-12-19 2016-09-21 成都永安制药有限公司 结核分枝杆菌tb-sa抗体酶联免疫法检测试剂盒及其制备方法
WO2017063657A1 (fr) * 2015-10-14 2017-04-20 Phlogo Aps Antagoniste peptidique dérivé de l'il-1ra
US20190142901A1 (en) * 2017-11-16 2019-05-16 Claresa Levetan Compositions and methods for treating or preventing type 1 diabetes using a biologic response modifier in combination with one or more islet or beta cell regeneration or replacement therapies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834590A (en) * 1995-02-22 1998-11-10 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
JP2002525126A (ja) * 1998-09-17 2002-08-13 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク Traf相互作用ext遺伝子ファミリーの新規遺伝子trex、並びにその診断及び治療への使用
US20040132644A1 (en) * 2001-10-16 2004-07-08 The Procter & Gamble Company Composition and method for treating diabetes
CA2609667C (fr) * 2005-05-25 2011-02-22 Curedm, Inc. Peptides, derives et analogues associes, et leurs methodes d'utilisation
SI2193142T1 (sl) * 2007-08-30 2015-05-29 Curedm Group Holdings, Llc Sestavek in postopek za uporabo proislet peptidov in analogov le-teh
WO2009049222A1 (fr) * 2007-10-12 2009-04-16 Curedm, Inc. Compositions et procédés d'utilisation du récepteur de peptide pro-îlot humain

Also Published As

Publication number Publication date
AU2013323462A1 (en) 2015-04-23
EP2900691A4 (fr) 2016-04-20
EP2900691A1 (fr) 2015-08-05
WO2014052611A1 (fr) 2014-04-03
JP2015533821A (ja) 2015-11-26

Similar Documents

Publication Publication Date Title
US7714103B2 (en) Peptides, derivatives and analogs thereof, and methods of using same
JP5960661B2 (ja) 膵島形成促進性ペプチドおよびそのアナログを使用する組成物および方法
US8785400B2 (en) Methods and compositions relating to islet cell neogenesis
US20050197292A1 (en) Compositions and methods for treating T-cell mediated pathological conditions
EP3202415A2 (fr) C1orf32 fusionnée avec le fragment fc pour le traitement de la sclérose en plaques, la polyarthrite rhumatoïde et d'autres maladies auto-immunes
US8911776B2 (en) Generation of new pancreatic beta cells
CA2886442A1 (fr) Generation de nouvelles cellules beta du pancreas
US9511110B2 (en) Generation of new pancreatic beta cells
US9133440B2 (en) Generation of new pancreatic beta cells
US20140120560A1 (en) Generation of new pancreatic beta cells

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20180926